Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Current vs. New Oral Semaglutide Formulations in Healthy Subjects
NCT04109508Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2019
- Primary completion
- Dec 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Novo Nordisk. Primary endpoint: Area under the semaglutide plasma concentration-time curve during a dosing interval at steady state at Day 84. Started Oct 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04109508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04109508.